Prostate cancer: The optimal number and location of cores for repeat biopsy.
J Stephen
JS
Jones
D000230:Adenocarcinoma / Q000601:surgery*; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D002243:Carbolines / Q000627:therapeutic use*; D003452:Cryosurgery; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology*; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D009119:Muscle Contraction / Q000502:physiology*; D009124:Muscle Proteins / Q000378:metabolism*; D009130:Muscle, Smooth / Q000378:metabolism*; D056887:Pelvic Organ Prolapse / Q000378:metabolism*; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D017698:Postmenopause / Q000378:metabolism*; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000601:surgery*; D012042:Registries; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014621:Vagina / Q000378:metabolism*
D000317:Adrenergic alpha-Antagonists; D001559:Benzhydryl Compounds; D002243:Carbolines; D018727:Muscarinic Antagonists; D009124:Muscle Proteins; D058986:Phosphodiesterase 5 Inhibitors